• FirefoxInstall the new Firefox »
  •  Dow Up0.86% Nasdaq Up0.90%

    Athersys, Inc. (ATHX)

    2.95 Up 0.36(13.90%) Mar 2, 4:00PM EST
    |Pre-Market : 2.95 0.00 (0.00%) 8:00AM EST - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    Athersys, Inc.
    3201 Carnegie Avenue
    Cleveland, OH 44115
    United States - Map
    Phone: 216-431-9900
    Fax: 216-361-9495
    Website: http://www.athersys.com

    Index Membership:N/A
    Full Time Employees:56

    Business Summary 

    Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. The company’s lead platform product, MultiStem cell therapy, an allogeneic stem cell product, which has Phase I clinical trials for the patients that have suffered an acute myocardial infarction, and leukemia or other blood-borne cancers; and is ongoing Phase II clinical trials for the patients suffering from inflammatory bowel disease (IBD) and ischemic stroke. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions. The company is also involved in identifying and developing small pharmaceuticals to treat obesity; related metabolic conditions, such as diabetes; and neurological indications, including schizophrenia. It has collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat IBD; and RTI Biologics, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market. The company was founded in 1995 and is headquartered in Cleveland, Ohio.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Athersys, Inc.

    Key Executives 
    Dr. Gil Van Bokkelen Ph.D., 54
    Co-Founder, Chairman and Chief Exec. Officer
    Mr. William Lehmann Jr., J.D., MBA, 49
    Pres, Chief Operating Officer and Sec.
    Dr. John J. Harrington Ph.D., 48
    Co-Founder, Chief Scientific Officer, Exec. VP and Director
    Ms. Laura K. Campbell CPA, 51
    Principal Financial Officer, Principal Accounting Officer and VP of Fin.
    Dr. Robert J. Deans Ph.D., 64
    Exec. VP of Regenerative Medicine
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders